Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Processa Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Processa Pharmaceuticals, Inc.

PCSA

Processa Pharmaceuticals, Inc.

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer therapies by modifying existing, well-understood cancer drugs to enhance efficacy and reduce toxicity. Its pipeline includes small molecules in Phase 2 trials targeting solid tumors, with a focus on improving safety profiles. The company leverages proprietary regulatory science to streamline development and aims for rapid adoption of more effective, less toxic cancer treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Processa Pharmaceuticals, Inc.

1
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports Increased Net Loss of $3.4 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports $13.6 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports $3.4 Million Net Loss for Q3 2025, Sees Asset Growth

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports Increased Net Loss and Asset Growth in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports Q1 2025 Financial Results with Increased Net Loss and Improved Liquidity

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports $11.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Processa Pharmaceuticals, Inc. Processa Pharmaceuticals Reports Net Loss of $3.4M, Increased R&D Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments